Robotic nephroureterectomy in the management of upper tract urothelial cancer: inching toward standard of care?
Sumit SainiRam Anil PathakAshok Kumar HemalPublished in: International urology and nephrology (2022)
Upper-tract urothelial carcinoma is a relatively rare malignancy. Current guidelines strongly recommend radical nephroureterectomy with bladder cuff excision and template-based lymph node dissection for all high-risk upper-tract urothelial carcinomas. Although the open approach is still considered the standard of care, evolution of minimally invasive approaches especially the robotic-assisted approach, has been found to be oncologically equivalent. Since its initial description in 2006, the surgical technique as well as the robotic surgical system has gone through a major evolution. With well-established advantages of the minimally invasive approach, robotic radical nephroureterectomy also has the ability to address both upper and lower urinary tract simultaneously without the need of patient repositioning, standardized single docking technique, ease of performing crucial steps like excision of ureterovesical junction and bladder cuff with watertight cystotomy closure, allowing perioperative instillation of intra-vesical chemotherapy. Robot-assisted radical nephro-ureterectomy and template-based lymph node dissection is gradually emerging as the current standard of care to achieve the best possible oncologic and functional outcomes. In this review article we are focusing on the evolution of this approach in the management of upper-tract urothelial carcinoma along with a review of oncologic outcomes.
Keyphrases
- urinary tract
- robot assisted
- minimally invasive
- healthcare
- palliative care
- quality improvement
- prostate cancer
- pain management
- rectal cancer
- spinal cord injury
- locally advanced
- metabolic syndrome
- radical prostatectomy
- early stage
- case report
- insulin resistance
- affordable care act
- high resolution
- squamous cell carcinoma
- type diabetes
- skeletal muscle
- squamous cell
- weight loss
- tandem mass spectrometry
- glycemic control